We Help Bring Innovative Therapies to Patients

MaSTherCell is a service company (CDMO - Contract Development and Manufacturing Organization) dedicated to the industrialization and production of cell and gene therapies for third parties. Its facilities enable cell therapy companies to benefit from state of the art infrastructures and world-recognized experts, thus accelerating the arrival of cell therapies on the market. At the heart of MaSTherCell is a team of 220 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. Their goal is to help customers providing innovative and affordable treatments to patients, in a fast and cost-efficient way.

Our Values

Engagement

Be part of the story

Transparency

The right information
at the right time

Agility

Be the change

Innovation

Breakthrough therapies

Team Spirit

One team, one spirit

Global Management

Chairperson | Director of Orgenesis

Vered
CAPLAN

Since 2008, Ms. Caplan has been CEO of Kamedis, a company focused on utilising plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was CEO of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the previous five years, Ms. Caplan has been a director of the…

Continue reading "VeredCAPLAN"
Managing Director at Great Point Partners

Jeffrey R.
JAY, M.D.

Dr. Jay has more than 30 years of private equity experience.  Prior to founding Great Point Partners in 2003, he was for 11 years a General Partner and the head of the health care group at J. H. Whitney & Co., an investment firm with over $6 billion in private equity, subordinated debt and hedge…

Continue reading "Jeffrey R.JAY, M.D."
CEO of MaSTherCell Global

Darren
HEAD

Darren Head is currently CEO and a board member at MaSTherCell.  He is on the board of GPP III portfolio company BioNova.  Mr. Head was the President and CEO of Cytovance Biologics (“Cytovance”), a former GPP I portfolio company and was a board member of GPP II portfolio company Clinical Supplies Management.  He has over…

Continue reading "DarrenHEAD"
R Mazanet LLC

Rosemary
MAZANET M.D., Ph.D.

Dr. Mazanet trained in medicine/oncology at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute before joining Amgen, Inc to lead clinical development in the early 1990s. After moving to public equity investing in 1998, she has been involved in specialty pharma and biotechnology as an Investor, Director and Strategic Advisor.

Continue reading "RosemaryMAZANET M.D., Ph.D."
Managing Director at Great Point Partners

Noah F.
RHODES

Mr. Rhodes has more than 11 years of private equity experience and joined Great Point Partners in 2006.  He is currently a board member of Axiom, Bionova, Corrona, MaSTherCell, Softbox Systems and Valenz.  Mr. Rhodes was previously a board member of Autism Learning Partners, Cytovance Biologics and Equian.  Prior to joining Great Point Partners, he…

Continue reading "Noah F.RHODES"
Senior Associate at Great Point Partners

Eddie A.
HJERPE

Prior to joining Great Point Partners in 2015, Mr. Hjerpe graduated from the University of Notre Dame with a M.S. in accountancy and a B.B.A in finance. He had completed internships at Sandler O’Neill & Partners, a boutique investment bank, and KPMG where he focused on financial due diligence consulting for private equity clients.

Continue reading "Eddie A.HJERPE"
Senior Partner and Chair of the Life Science Practice at Pearl Cohen Zedek Latzer Baratz

Mark
COHEN

Mark S. Cohen is a Founder, Senior Partner and Chair of the Life Science Practice Group at Pearl Cohen Zedek Latzer Baratz, LLP. Pearl Cohen has offices in New York, Boston, Los Angeles, London and Israel. He is admitted to the New York bar. He is a registered patent attorney in the United States experienced…

Continue reading "MarkCOHEN"
President

Denis
BEDORET

Denis Bedoret joined MaSTherCell in October 2016 as Chief Business and Administration Officer. He was then appointed as General Manager in January 2017 with the ambition to pursue the global development of MaSTherCell’s activities. He previously held the position of COO at Quality Assistance, a leading European analytical CRO where he was also a member…

Continue reading "DenisBEDORET"
COO

Éric
MATHIEU

With over 15 years of experience in the biopharmaceutical industry and three years in the food industry, Eric’s main areas of expertise are people and field management. At GSK Belgium, he was a significant player in vaccine development, industrialization, process transfer and manufacturing of cell culture processes, while at Baxter Switzerland he developed his cGMP…

Continue reading "ÉricMATHIEU"
CSO

Gisèle
DEBLANDRE

Gisèle Deblandre graduated from the Université Libre de Bruxelles, Belgium, and holds a Ph.D. in Molecular and Cell Biology. Gisèle ‘s career spans 17 years in R&D in life sciences, with strong expertise in cell biology and mechanisms of cell differentiation. After six years in developmental biology at the Salk Institute (San Diego, California), she…

Continue reading "GisèleDEBLANDRE"
HR Manager

Élodie
NOËL

Elodie took a Master in Biology at the University of Pisa, supplemented by an HR diploma obtained at ICHEC (Brussels Management School). Subsequently, she worked as Office and Account Manager for an IT leasing company and for 5 years at Kelly Scientific Resources. As Manager of the Belgian Branch of Kelly Scientific, Elodie has developed…

Continue reading "ÉlodieNOËL"
CTO

Jean-François
CHAUBARD

Jean-François is a French engineer graduated from the National Institute of Applied Science of Toulouse. He has been working in the Biotech industry for the past 23 years including 12 years within GSK Vaccines in Rixensart. Over this long period, he was involved in the development and scale-up of different industrial processes based on mammalian…

Continue reading "Jean-FrançoisCHAUBARD"
General Manager US

David
WALSHAW

David joined the MaSTherCell US team as General Manager and Vice President of Operations in mid-2019. David brings more than 30 years of pharma/biopharma CDMO experience, with the past 20 years in senior leadership positions. With a passion for developing organizations, implementing business strategy and enhancing the client experience, David is charged with growing the…

Continue reading "DavidWALSHAW"

History

Timeline About

2011
  • Creation of the company.
  • ULB spin-off assisted by private investors.

2014
  • Manufacturing licence obtained for Europe.
  • Start of production activities for clinical studies.

2015

Orgenesis acquires a stake in the capital.

2016

MaSTherCell becomes a leader in immunotherapy.

2017

SFPI acquires a stake in the capital.

2018
  • Creation of MaSTherCell Global.
  • Great Point Partners acquires a stake in the capital.

  • Inauguration of an extension of a 600 m2 production area.

2019

Start of MaSTherCell USA activities.

2021

Inauguration of the commercial dedicated plant (5700 m2).